You are here

FDA Approves Once-a-Month Actonel

PrintPrint
Release Date: 
Wednesday, June 18, 2008

ROSEMONT, IL – Osteoporosis is a serious, widespread and growing public health threat, according to the National Osteoporosis Foundation (NOF), a founding member of the United States Bone and Joint Decade (USBJD). Like NOF, the USBJD welcomes any new FDA approved treatment options, such as Once-a-Month ACTONEL(r), that will help patients address this prevalent disease. NOF estimates 10 million Americans age 50 and older have osteoporosis and another 34 million are at risk for the disease.

The Bone and Joint Decade is an international movement sanctioned by the United Nations/World Health Organization. Officially proclaimed by the U.S. President, the mission of the United States Bone and Joint Decade (USBJD) 2002-2011 is to promote and facilitate collaboration among the public, patients, and organizations to improve bone and joint health through research, education, and advocacy.

For information on the burden of osteoporosis in the United States, visit www.boneandjointburden.org.

For information on the USBJD’s public education program on bone health and osteoporosis, Fit to a T, visit www.fit2t.org.

www.usbjd.org
[email protected]